# A Study to Evaluate the Effects of ABX-1431 on Patients With Tourette Syndrome

> **NCT03058562** · PHASE1 · COMPLETED · sponsor: **Abide Therapeutics** · enrollment: 23 (actual)

## Conditions studied

- Tourette Syndrome
- Chronic Motor Tic Disorder

## Interventions

- **DRUG:** ABX-1431
- **DRUG:** Placebo Comparator
- **DRUG:** ABX-1431

## Key facts

- **NCT ID:** NCT03058562
- **Lead sponsor:** Abide Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-01
- **Primary completion:** 2017-10-04
- **Final completion:** 2017-10-04
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03058562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03058562, "A Study to Evaluate the Effects of ABX-1431 on Patients With Tourette Syndrome". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03058562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*